Prepared by:
File Name Description Software Version File Size __________________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 97 SR-1 39KB 7 pages Contents: Cover, Title Page, Preface, Structured Abstract 02conts.doc Microsoft Word® Document MS Word® 97 SR-1 24KB 2 pages Contents: Table of Contents 03summ.doc Microsoft Word® Document MS Word® 97 SR-1 85KB 12 pages Contents: Summary: Overview; Reporting the Evidence; Methodology; Findings; Priorities for Future Research 04chap1.doc Microsoft Word® Document MS Word® 97 SR-1 70KB 11 pages Contents: Chapter 1. Introduction: Scope and Objectives; Key Questions; Background; Clinical Practice Guidelines for Anemia in Chronic Renal Failure; Epoetin; Table 1. FDA-approved uses of epoetin alfa and dosing recommendations 05chap2.doc Microsoft Word® Document MS Word® 97 SR-1 65KB 10 pages Contents: Chapter 2. Methodology: Overview; Technical Advisors; Search Strategy for the Identification of Articles; Determining Study Eligibility; Stages of Study Selection; Table 2. Reasons for study exclusion; Data Abstraction; Evaluation of Study Quality 06chap3.doc Microsoft Word® Document MS Word® 97 SR-1 278KB 47 pages Contents: Chapter 3. Results and Conclusions: Overview; Part I: Adult Patients with Chronic Renal Failure; Table 3. Overview of study quality and relevance: Results and conclusions, Part I; Table 4. Overview of outcomes reported in each study: Results and conclusions, Part I; Figure 1. Mean Mortality Rate as a Function of the Average Hematocrit Value; Table 5. Summary of results for Pickett, Theberge, Brown, et al., 1999; Part II: Pediatric Patients with Chronic Renal Failure; Table 6. Summary of observed effect on blood pressure in selected studies using epoetin to raise Hct over 30 percent in pediatric patients; Part III: Subpopulations of Interest (With or Without Chronic Renal Failure); Table 7. Overview of study quality: Results and conclusions, Part III; Table 8. Overview of outcomes reported in each study: Results and conclusions, Part III 07chap4.doc Microsoft Word® Document MS Word® 97 SR-1 33KB 2 pages Contents: Chapter 4. Future Research 08refs.doc Microsoft Word® Document MS Word® 97 SR-1 38KB 4 pages Contents: References 09etbls.doc Microsoft Word® Document MS Word® 97 SR-1 293KB 47 pages Contents: Acronyms and Abbreviations Used in Evidence Tables; Evidence Table 1. Randomized controlled clinical studies; Evidence Table 2. Nonrandomized controlled clinical trials; Evidence Table 3. Studies reporting cross-sectional analyses; Evidence Table 4. Mortality; Evidence Table 5. Quality of life; Evidence Table 6. Hospital utilization; Evidence Table 7. Use of red blood cell transfusion; Evidence Table 8. Cardiac health outcomes; Evidence Table 9. Cardiac intermediate health outcomes; Evidence Table 10. Exercise performance intermediate health outcomes; Evidence Table 11. Cognitive function intermediate health outcomes; Evidence Table 12. Sleep pattern intermediate health outcomes; Evidence Table 13. Nutritional status intermediate outcomes; Evidence Table 14. Treatment-related morbidity associated with normalization of hematocrit; Evidence Table 15. Randomized controlled clinical studies; Evidence Table 16. Studies reporting cross-sectional analyses; Evidence Table 17. Studies addressing impact of cardiovascular disease on relationship between hematocrit and outcomes; Evidence Table 18. Studies addressing impact of cerebrovascular disease on relationship between hematocrit and outcomes 10biblio.doc Microsoft Word® Document MS Word® 97 SR-1 328KB 51 pages Contents: Bibliography 11appa.doc Microsoft Word® Document MS Word® 97 SR-1 27KB 5 pages Contents: Appendix A. Technical Advisory Group, External Reviewers, and Medical Advisory Panel 12appb.doc Microsoft Word® Document MS Word® 97 SR-1 24KB 2 pages Contents: Appendix B. Data Abstraction Forms: Renal 13appc.doc Microsoft Word® Document MS Word® 97 SR-1 22KB 1 page Contents: Appendix C. Acronyms and Abbreviations __________________________________________________________________________________________________________
AHRQ Publication No. 01-E060
Current as of June 2001
Internet Citation:
Use of Epoetin for Anemia in Chronic Renal Failure. File Inventory, Evidence Report/Technology Assessment Number 29. AHRQ Publication No. 01-E016, June 2001. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/epcrfinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services